Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Prices $10 Million Registered Direct Offering
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Present at Biotech Showcase 2024
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Present at Two Investment Conferences in October 2023
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.